跳至主要内容
临床试验/DRKS00013925
DRKS00013925已完成未知

Early evaluation of therapy response (targeted therapy and immunotherapy) in patients with metastasized malignant melanoma by multiparametric PET/MR imaging. - GK-MR/PET Tü-004

niversitätsklinikum Tübingen, Radiologische Klinik, Diagnostische & Interventionelle Radiologie0 个研究点目标入组 62 人开始时间: 2018年1月29日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
62

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 99 Years(—)
性别
All

入选标准

  • Patient with diagnosed unresectable malignant melanoma stage IV,
  • -Age: =18 years,
  • -Planned systemic therapy with new therapies: BRAF/MEK inhibitors, Anti-CTLA-4/Anti-PD-1 antibodies,
  • -Clinically indicated routine PET/CT (baseline t0) demonstrating at least one measurable lesion,
  • -PET/CT for baseline-staging and therapy monitoring (clinical indication required),
  • -Informed consent.

排除标准

  • -Contraindications for MR-imaging (metal implants, claustrophobia, etc.),
  • -Contraindications for gadolinium-based contrast agent,
  • -Acute infections or other acute diseases,
  • -Pregnant or breast-feeding women,
  • -Disability for informed consent

研究者

发起方
niversitätsklinikum Tübingen, Radiologische Klinik, Diagnostische & Interventionelle Radiologie

相似试验